
C difficile: Summer 2025 Clinical Recap
A June–September C diff roundup spanning diagnostics and stewardship debates, microbiome-based therapies and FMT optimization, prevention trials and funding, real-world outcomes, and persistent gaps in clinician practice and public awareness.
June
Study questions added value of enzyme immunoassays alongside PCR, citing sensitivity concerns and clinical impact.
ASM Microbe data emphasize NAAT’s role in outpatient CDI diagnosis and spotlight PPI-associated risk in older patients.
An AI-guided infection-prevention bundle increased stewardship activity despite no significant CDI incidence reduction.
July
Multicenter US experience supports RBL as a safe, effective microbiota-based option with sustained rCDI remission.
Randomized data leave the role of prophylactic oral vancomycin for CDI prevention unresolved in at-risk patients.
Patient perspective details CDI during pregnancy, recovery challenges, and peer-support resources through the Peggy Lillis Foundation.
Multidose capsules or colonoscopy after extended antibiotic pretreatment yield the highest FMT success rates for rCDI.
August
Personalized gut microbiome modeling may identify CDI colonization risk and guide targeted probiotic interventions.
Colonization status drives hospital-onset CDI risk, suggesting prevention must pair stewardship with targeted colonization control.
Systematic review finds FMT and standardized microbiome products outperform antibiotics for rCDI efficacy and safety.
Electronic prompts improve adherence but reinforce that consistent, thorough hand hygiene remains central to CDI prevention.
September
New funding advances a pivotal prophylaxis study aiming to reduce CDI incidence in high-risk populations.
Clinician responses reveal departures from guideline-concordant CDI management and identify practical barriers to optimal diagnosis and treatment.
Despite rising awareness, gaps persist, underscoring the need for public education on C difficile transmission, risk, and prevention.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
































































































































































































































































































